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The prognosis for newly diagnosed multiple myeloma
(NDMM) has improved with the advent of new agents, but
outcome in some patients remains very poor. Identifying
patients with high-risk disease early opens up the prospect
of stratified treatment [1–3].
Biomarkers including chromosomal aberrations t(4;14),
t(14;16), and t(14;20) translocations, gain of 1q and deletion
of 17p, detected by fluorescence in situ hybridization
(FISH) or multiplex ligation-dependent probe amplification
(MLPA) and qRT-PCR-based translocation detection, have
been associated with adverse outcome and co-occurrence of
≥2 such aberrations (a double-hit) is predictive of especially
aggressive MM [4, 5]. Multiple gene expression profiles
(GEP) have been reported to be associated with outcome,
but so far only EMC92 and UAMS GEP70 have been
developed into validated clinical tests, marketed as SKY92
MMprofiler and MyPRS, respectively [6–9].
To examine the combined predictive value of high-risk
chromosomal abnormalities and SKY92 risk GEP we stu-
died 329 NDMM patients from the NCRI Myeloma XI trial
(ISRCTN49407852) who received intensive therapy
(Supplementary Table 1) and validated findings in Medical
Research Council (MRC) Myeloma IX trial patients
(Supplementary Methods) [10, 11]. In both cohorts of
patients purified (>95%) CD138-positive tumor cells were
immunomagnetically selected and DNA and RNA were
extracted using QIAGEN (Hilden, Germany) Allprep kits.
Chromosomal aberrations, including high-risk lesions
t(4;14), t(14;16), t(14;20), gain(1q), and del(17p), were
assessed using qRT-PCR (Thermo Fisher, Darford, UK)
and MLPA (MRC Holland, Amsterdam, The Netherlands),
as previously reported (Supplementary Methods) [4]. GEP
risk status was determined on a diagnostic Affymetrix
GeneChip 3000 Dx v2.0 system (Thermo Fisher) using
the SKY92 MMProfiler (SkylineDx, Rotterdam, The
Netherlands) (Supplementary Methods). Statistical analyses
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were performed in R (version 3.5.1) as detailed in Supple-
mentary Methods.
MMprofiler assay results by SkylineDx identified 81 of
the 329 Myeloma XI trial patients (24.6%) to have a SKY92
high-risk tumor signature (Supplementary Table 2). SKY92
high-risk patients had significantly shorter PFS (median
16.0 vs. 33.8 months; HR 2.6, 95% CI: 2.0–3.5; P= 4.1 ×
10−11) and OS (median 36.7 months vs. not reached; HR
3.9, 95% CI: 2.7–5.7; P= 2.5 × 10−13) (Supplementary
Fig. 1; Table 1), regardless of induction regimen and
posttransplant randomization (Supplementary Figs. 2, 3;
Supplementary Tables 3–5). Specifically, patients with
SKY92 high-risk disease did not derive statistically sig-
nificant benefit from lenalidomide single agent maintenance
therapy (Fig. 1; Supplementary Fig. 3).
There was partial overlap between patients with GEP or
chromosomal high-risk markers (Fig. 1, Supplementary
Table 2), with 6.1% (20/329) of patients showing SKY92
positivity but absence of chromosomal high-risk markers.
We analyzed prognostic association of molecular and clin-
ical risk markers in a multivariable Cox proportional hazard
model and found presence of SKY92 high-risk (HR 2.7,
95% CI: 1.8–4.2; P= 4.4 × 10−6), adverse translocations
(HR 1.8, 95% CI: 1.2–2.9; P= 0.007), and del(17p) (HR
2.5, 95% CI: 1.5–4.1; P= 0.0007) to be independently
associated with shorter OS and SKY92 high-risk (HR 2.1,
95% CI: 1.5–3.0; P= 4.8 × 10−6) and adverse transloca-
tions (HR 1.9, 95% CI: 1.4–2.6; P= 0.0002) with shorter
PFS (Table 1). Results were similar when analyzing GEP
risk status with the UAMS GEP70 signature: by multi-
variable analysis UAMS GEP70 high-risk (HR= 2.54; 95%
CI: 1.56–4.13; P= 1.8 × 10−4), presence of del(17p)
(HR= 2.22; 95% CI: 1.32–3.72; P= 0.0025), and adverse
translocation (HR= 2.11; 95% CI: 1.35–3.28; P= 9.5 ×
10−4) were independently associated with shorter OS.
However, GEP70 was not independently associated with
shorter PFS (Supplementary Table 6).
One hundred and sixty-one patient tumors carried no
chromosomal high-risk marker, of which 20 (12%) were
SKY92 high-risk. The presence SKY92 GEP high-risk in
isolation was significantly associated with shorter PFS
(HR= 3.18; 95% CI: 1.86–5.46; P= 2.6 × 10−5; median
Table 1 Univariate and multivariate Cox proportional hazard survival analyses of genetic, gene expression, and clinical risk markers for PFS and
OS for 329 representative Myeloma XI NDMM patients from induction randomization.
Univariate analysis Multivariate analysis
Progression free survival Progression free survival
HR (95% CI) Wald P HR (95% CI) Wald P
SKY92 high-risk 2.6 (1.96–3.45) 4.08 × 10−11 SKY92 high-risk 2.14 (1.54–2.96) 0.00000475
Hyperdiploid 0.74 (0.57–0.95) 0.0198 Hyperdiploid 0.93 (0.7–1.24) 0.634
Adverse translocation 2.04 (1.53–2.72) 1.12 × 10−06 Adverse translocation 1.89 (1.36–2.62) 0.00015
Del(1p) [CDKN2C] 1.47 (1–2.18) 0.0514 Del(1p) [CDKN2C] 1.01 (0.65–1.56) 0.979
Del(17p) [TP53] 1.63 (1.09–2.42) 0.016 Del(17p) [TP53] 1.32 (0.87–2.0) 0.198
Gain(1q) 1.44 (1.11–1.88) 0.00634 Gain(1q) 0.88 (0.65–1.2) 0.425
Age 1.04 (1.02–1.06) 0.00012 Age 1.04 (1.02–1.06) 0.000144
Induction randomization 0.77 (0.59–0.99) 0.0417 Induction randomization 1.2 (0.92–1.55) 0.176
ISS 1.33 (1.12–1.58) 0.0012 ISS 1.13 (0.95–1.36) 0.176
n= 328, events= 232
Overall survival Overall survival
HR (95% CI) Wald P HR (95% CI) Wald P
SKY92 high-risk 3.94 (2.73–5.69) 2.54 × 10−13 SKY92 high-risk 2.72 (1.78–4.16) 0.00000396
Hyperdiploid 0.6 (0.42–0.87) 0.00717 Hyperdiploid 0.91 (0.6–1.37) 0.647
Adverse translocation 2.5 (1.72–3.64) 1.67 × 10−06 Adverse translocation 1.85 (1.19–2.88) 0.0061
Del(1p) [CDKN2C] 2.38 (1.49–3.79) 0.000271 Del(1p) [CDKN2C] 1.29 (0.76–2.2) 0.343
Del(17p) [TP53] 3.02 (1.87–4.87) 5.76 × 10−06 Del(17p) [TP53] 2.48 (1.48–4.17) 0.000602
Gain(1q) 2.39 (1.66–3.44) 2.98 × 10−06 Gain(1q) 1.3 (0.85–1.97) 0.222
Age 0.62 (0.43–0.9) 0.0113 Age 1.02 (0.99–1.05) 0.2
Induction randomization 0.62 (0.43–0.9) 0.0113 Induction randomization 1.31 (0.9–1.91) 0.153
ISS 1.38 (1.08–1.76) 0.0101 ISS 1.09 (0.84–1.43) 0.512
N= 328, events= 117
Statistically significant P < 0.05 values are in bold.
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15.8 vs. 41.7 months) and OS (HR= 2.42; 95% CI:
1.04–5.67; P= 0.04; estimated 4 year OS 55% vs. 86%;
Supplementary Fig. 4; Supplementary Table 7).
We have previously demonstrated the adverse prognosis
of double-hit tumors, defined by co-occurrence of ≥2
chromosomal high-risk markers [4]. SKY92 and double-hit
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were independently prognostic by multivariable analysis,
with HRs 2.9 (95% CI: 1.9–4.2; P= 2.6 × 10−7) and 2.3
(95% CI: 1.5–3.6; P= 0.0002) for OS and HRs 2.0 (95%
CI: 1.5–2.8; P= 6.8 × 10−6) and 1.6 (95% CI: 1.2–2.3; P=
0.005) for PFS, respectively (Supplementary Table 8).
Results were consistent when PFS and OS were measured
from maintenance randomization (Supplementary Table 8).
We defined four risk groups combining predictive SKY92
and chromosomal high-risk markers: double-hit AND
SKY92 (9.7% of pts), double-hit OR SKY92 (23.4% of
pts), a single chromosomal high-risk marker (24.0% of pts),
and no risk marker (42.9% of pts). Hazard ratios for OS
were 11.0 (95% CI: 6.3–19.1; P < 2.2 × 10−16), 3.8 (95%
CI: 2.3–6.3; P= 2 × 10−7), and 1.9 (95% CI: 1.1–3.3; P=
0.03) compared with those without risk markers, and HRs
for PFS were 4.5 (95% CI: 3.0–6.9; P= 2.3 × 10−12), 2.3
(95% CI: 1.7–3.3; P= 4.4 × 10−7), and 1.3 (95% CI:
0.9–1.9; P= 0.118), respectively (Fig. 1; Supplementary
Table 9). Results were consistent when PFS and OS were
measured from time point of ASCT (Supplementary Fig. 5;
Supplementary Table 9).
Of note, lenalidomide single agent maintenance mark-
edly extended PFS in patients with a single chromosomal
high-risk marker (HR 0.11; 95% CI: 0.03–0.41; P=
0.0001) or no risk marker (HR 0.26; 95% CI: 0.12–0.58;
P= 0.001) when compared with observation. In contrast,
those with SKY92 and/or double-hit (HR 0.67; 95% CI:
0.12–1.72, P= 0.24; HR 0.67; 95% CI: 0.32–1.37; P=
0.27, respectively) did not derive consistent benefit from
lenalidomide maintenance (Supplementary Fig. 6).
Patients with combined double-hit and SKY92 high-risk
status (9.7%) had poor survival outcomes: all patients
(100%) progressed within 48 months from initial randomi-
zation and predicted OS at 48 months was 12.5% (Fig. 1).
To confirm ultra-high-risk behavior of combined double-hit
and SKY92 tumors in an independent trial, we analyzed 116
patients from the intensive, transplant treatment arm of MRC
Myeloma IX. Eight (6.9%) patients showed double-hit and
EMC92 ultra-high-risk; all patients progressed within
36 months and died within 48 months. Meta-analysis using a
random-effect model showed a HR for OS of 6.0 (95% CI:
4.1–8.9; P= 4.8 × 10−20) and HR of 3.5 (95% CI: 2.5–4.9;
P= 6.9 × 10−13) for PFS for patients with combined GEP
and double-hit tumors (Supplementary Fig. 7).
After accounting for GEP and chromosomal high-risk
status, ISS and serum LDH were not predictive of outcome
(Supplementary Fig. 8; Supplementary Table 10). We found
significant overlap of these clinical and molecular risk
markers: frequency of ISS 3 was higher in SKY92 high-risk
vs. non-high-risk (38% vs. 21%; P= 0.003; Supplementary
Fig. 9) and in those with multiple chromosomal high-risk
risk lesions (21.5% without vs. 28.6% with single hit vs.
43.8% with double-hit). Only 15.6% of double-hit tumor
patients were ISS 1 at diagnosis (Supplementary Fig. 9),
whereas 71% of patients with ISS 3 carried one or more
chromosomal or SKY92 high-risk marker. Similarly, base-
line LDH was higher in patients with SKY92 or double-hit
tumors vs. those without (Supplementary Figs. 9, 10).
We furthermore interrogated a range of risk signatures
beyond binary (high-risk/non-high-risk) clinical read-out.
Quantitative risk scores were correlated for most clinical
signatures, most markedly EMC92 and GEP70 (r= 0.79;
P < 0.001) (Supplementary Fig. 11). The EMC92 score
(r= 0.64, P < 0.001) as well as most others also correlated
with the in vitro model derived Proliferation Index (Sup-
plementary Fig. 11).
Extreme copy number abnormalities (CNAs; amplifica-
tion (≥4 copies) or homozygous deletion) have recently
been proposed as exclusive drivers of high-risk MM [12],
prompting us to investigate the correlation of quantitative
CNAs with GEP risk scores. Median EMC92 scores were
higher in tumors with gain(1q) vs. those without (P= 2.1 ×
10−8) but there was no difference between gain (three
copies) and amplification of 1q (≥4 copies) (P= 0.56;
Supplementary Fig. 12), with a wide range of GEP scores in
the latter. Tumors with deletion 17p had significantly higher
median EMC92 GEP scores than those without deletion.
Homozygous del(17p) was rare (n= 2), as expected, not
allowing for formal comparison (Supplementary Fig. 12).
Tumors with high-risk translocations had on average higher
EMC92 scores than those without (Supplementary Fig. 13).
Our results demonstrate the prospective prognostic
validity of SKY92 profiling in the wider context as a means
of identifying patients at diagnosis who have high-risk MM,
and show the independent association of SKY92 and high-
risk chromosomal aberrations with outcome [9]. Our results
highlight the molecular diversity of MM and demonstrate
that single time point combined GEP and chromosomal
profiling at diagnosis can predict clinical outcome with
significant precision, in line with recent findings across
multiple solid cancers [13, 14].
Fig. 1 Patient outcome in context of GEP and chromosomal high-
risk markers and their respective frequencies and distribution in
Myeloma XI. Kaplan–Meier plot of Myeloma XI trial patients (n=
329) in context of SKY92 risk profiling for (a) PFS, (b) OS from
maintenance randomization, with survival curves for patients rando-
mized to lenalidomide or observation plotted separately. Log-rank
P values displayed. c, d Kaplan–Meier plots of molecular risk groups
defined by absence of any high-risk marker, presence of a single
genetic risk marker, presence of either double-hit or SKY92 high-risk
or combined double-hit and SKY92 high-risk for c PFS, d OS from
induction randomization. e Venn diagram of patients with tumors
positive for validated genetic risk markers adverse translocations, gain
(1q), del(17p), SKY92 GEP high-risk. % is relative to 188 patients
with high-risk lesions, (%) relative to all patients (n= 329) in the
study. Frequency represented by gray color coding, with darker gray
indicating higher frequency.
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We furthermore demonstrate that in context of combined
SKY92 and chromosomal profiling, ISS and LDH are not
independently predictive. This is perhaps not unexpected,
since ISS and LDH are clinical surrogate markers for tumor
proliferation, which is assessed by combined GEP and
double-hit profiling. Our analysis was, however, limited to
younger and fitter, transplant-eligible patients and clinical
risk markers such as ISS may have greater and independent
relevance in older or frailer patients [15].
Our results demonstrate that patients with double-hit or
GEP high-risk status are unlikely to benefit from current
treatment approaches, including single agent lenalidomide
maintenance therapy. In such patients intensified ongoing
therapy with combination agents may be beneficial [3].
Such an assertion will be prospectively assessed in clinical
studies such as the risk stratified UK OPTIMUM
(MUKnine) trial (NCT03188172).
In conclusion, our findings support the further adoption
of molecular biomarkers to stratify NDMM patient therapy.
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